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ABSTRACT
The 5th International Porto Congress of Multi-
ple Sclerosis took place between the 14th and
16th of February 2019 in Porto, Portugal. Its
intensive programme covered a wide-range of
themes—including many of the hot topics,
challenges, pitfalls and yet unmet needs in the
field of multiple sclerosis (MS)—led by a num-
ber of well-acknowledged world experts. This
meeting review summarizes the talks that took
place during the congress, which focussed on
issues in MS as diverse as the development and
challenges of progressive MS, epidemiology,
differential diagnosis, medical management,
molecular research and imaging tools.
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Key Summary Points
Multiple sclerosis (MS) is an immune-
driven neurological disease with a
conspicuously heterogeneous distribution
that affects approximately 2.3 million
people worldwide.
The 5th International Porto Congress of
Multiple Sclerosis took place on February
2019 in the city of Porto, Portugal, and
brought together a number of world-
known experts in the field who shared
their latest discoveries and discussed
targets in MS healthcare that have yet to
be met.
This review summarizes the main talks
given during the congress, including the
state-of-the-art description, ground-
breaking projects and promising results.
Discussed topics are as diverse as the
epidemiology of MS in different
continents, the development of and
pitfalls in progressive MS, differential
diagnosis and related diseases, medical
management, cognitive impairment and
its consequences, pregnancy and family
planning and advances in molecular
research and imaging techniques.
INTRODUCTION
Multiple sclerosis (MS) is an immune-driven
neurological disease that has a profound impact
on patients’ quality of life (QOL). MS affects
approximately 2.3 million people worldwide,
and its prevalence is remarkably heterogeneous,
varying from 50 to 300 patients per 100 000
inhabitants [1]. Most patients are diagnosed
during early adult life, and women have a
markedly higher incidence. Overall, there is
evidence for MS onset being triggered by envi-
ronmental factors in genetically predisposed
individuals, such as low vitamin D levels,
cigarette smoking and obesity in early life [1].
Approximately 85–95% of the patients present a
relapsing–remitting course (RRMS),
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characterized by relapsing phases intertwined
with periods of neurological stability [2, 3].
However, MS can also assume a progressive
course, characterized by a steadily increasing
neurological decline, either from the onset
(primary progressive MS [PPMS]), or within
15–25 years of RRMS diagnosis (secondary pro-
gressive MS [SPMS]) [2, 3]. The MS diagnosis
remains challenging and relies on the integra-
tion of clinical, laboratory and imaging find-
ings, with the McDonald criteria being used by
most neurologists [2].
The 5th International Porto Congress of
Multiple Sclerosis, held in Porto (Portugal) in
February 2019, had an ambitious programme
and covered many of the hot topics, challenges
and unmet needs in the MS field. In front of an
audience composed of researchers, clinicians
and patients, several internationally acknowl-
edged specialists presented state-of-the-art,
ground-breaking projects and promising results.
The aim of this article is to provide an overview
of the main issues discussed in the meeting and
is based on previously conducted studies by the
authors.
PROGRESSIVE MS: DEVELOPMENTS
AND PITFALLS
Giancarlo Comi (San Raffaele Hospital, Italy)
gave the meeting’s magistral conference, in
which he discussed the main advances in pro-
gressive MS and the as yet unmet needs of
patients suffering from this clinical form of MS.
Immunopathological studies have revealed a
large overlap of lesion load between relapsing
and progressive MS courses, with some qualita-
tive differences in the distribution of lesion
subtypes [4–6]. In progressive MS, most of the
lesions are inactive, with only a small propor-
tion of active lesions in the late phase and a
predominance of chronically active, slowly
expanding lesions, i.e. the smoldering lesions
characterized by a hypocellular demyelinated
core with a variable axonal degeneration and
hypercellular edge of activated microglia and
reactive astrocytes [4, 5]. Subpial cortical
lesions, in contrast, are abundant in the pro-
gressive forms of the disease (either PPMS or
SPMS), but are rarely seen among early RRMS
[3–5, 7].
Moving from the disease’s pathology to its
clinical phenotype, Comi underscored the
recent changes made to the classification of
progressive MS: whereas the focus was tradi-
tionally placed on the presentation of the pro-
gressive phenotype (primary vs. secondary), the
new classification now focusses on disease
activity and disability evolution [8]. In fact, and
while the terms PPMS and SPMS are still used,
two new concepts were introduced into this
classification: disease activity (based on the
presence of relapses and/or active lesions, such
as new T2 magnetic resonance imaging (MRI)
lesions and/or gadolinium-enhancing lesions)
and disability evolution (i.e. a gradual worsen-
ing of disability in a relapse-independent fash-
ion or stable disability) [8]. For Comi, this
classification provides a more accurate descrip-
tion of the true nature of progressive forms of
MS because the presence/absence of disease
activity has clear treatment implications and
there is a remarkable variation in the speed of
disability progression among different patients.
The identification of the key factors that drive
this variability will be a critical step for a better
understanding of the disease and, ultimately,
for improving patients’ care.
Another aspect addressed by Comi was the
need for better diagnostic and monitoring tools.
In this context, he highlighted the recent
advances in MRI technology, as well as the
importance of measuring brain and spinal cord
atrophy and of complementing the traditional
assessments with functional measures, such as
evoked potentials and optical coherence
tomography (OCT) (some of these aspects were
discussed in more detail by other speakers and
are described in following sections of this arti-
cle). He also underscored the role of body fluid
biomarkers, highlighting the particularly
attractive findings made in the context of neu-
rofilaments [9].
Finally, Comi mentioned the lack of thera-
peutic alternatives for progressive MS: in fact,
despite the notable growth of the RRMS thera-
peutic armamentarium, few disease-modifying
drugs (DMDs) have shown positive results in
patients with progressive MS. Those which
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did—siponimod and ocrelizumab—mostly tar-
get inflammatory elements of the disease cas-
cade [10, 11]. Nonetheless, Comi considered
that an improvement of care in progressive MS
will require looking beyond the inflammatory
pathway, extending research towards neuro-
protective and repair-promoting strategies.
EPIDEMIOLOGY AND RECENT
ADVANCES
The geographical distribution of MS is one of
the most striking aspects of this disease’s epi-
demiology: with a number of exceptions, its
prevalence seems to increase with increasing
distance from the equator [1]. However, there
are also some remarkable geographical dispari-
ties in the availability of neurologists and diag-
nostic tools, as well as in MS severity and
progression. To achieve an integrated insight
into these issues, specialists from all over the
world were invited to discuss the main aspects
of MS epidemiology in their respective regions
and the main concerns of neurologists, as well
as some of the latest developments in research.
Ays¸e Altintas¸ (Koc¸ University, Turkey) gave a
general overview of MS prevalence and state of
care in Turkey. Interestingly, although Turkey
has long been considered to be a low-incidence
country—the 2013 MS International Founda-
tion report estimates its prevalence to be in the
range 20.01–60 cases per 100,000 inhabitants
[12]—recently published articles have suggested
otherwise. For example, Bo¨ru¨ et al. have asses-
sed the prevalence of MS among the inhabitants
of three Turkish cities, two of which are located
in the Black Sea region (Artvin and Ordu) and
one located in the Mediterranean region
(Gazipas¸a) [13]. These cities, which were chosen
due to their location and low immigration rate,
were reported to have an MS prevalence of 18.6,
55.5 and 52.0 cases per 100,000 inhabitants,
respectively [13]. Another study, which focus-
sed on the prevalence of MS in the Middle Black
Sea Region of Turkey, reported 43.2 cases per
100,000 inhabitants [14]. Other studies have
described an MS prevalence of 41.1 cases per
100,000 inhabitants of Geyve (a rural area in the
Black Sea Region) and of 101.4 cases per 100,000
inhabitants of the district of Maltepe (Istanbul)
[15, 16]. Consequently, it is now believed that
the true prevalence of MS in Turkey should be
within these latter limits. On the other hand,
with respect to specialist care and resources,
Turkey seems to be in a fairly good position.
According to Altintas¸, there are over 2000 neu-
rologists in the country, of whom 118 are cur-
rently dedicated to studying and managing MS
and other demyelinating diseases. The McDon-
ald criteria are usually applied for diagnosis, and
the number of available MRI scanners exceeds
800. Most therapies and DMDs are available and
easily accessible to patients (through the public
health system and/or private health insur-
ances), and treatment strategies follow the
international guidelines with minor local
adjustments.
Najib Kissani (University Hospital Mohamed
VI, Morocco) addressed the prevalence and the
progression of MS in Africa. African countries
can be divided into three different zones
according to their MS prevalence: the north,
comprising countries such as Morocco, Tunisia,
Egypt and Algeria, which is described as a mild
to high prevalence area (30–80 cases per
100,000 inhabitants); the south, namely South
Africa, which is a mild prevalence area (10–30
cases per 100,000 inhabitants); and the rest of
sub-Saharan Africa, which is a very low preva-
lence area (\ 5 cases per 100,000 inhabitnts).
This scenario, however, is likely driven by a
high rate of underdiagnosis, stemming from the
worrisome lack of resources and specialists in
many sub-Saharan countries. Interestingly, and
despite the low prevalence, MS cases in Africa
seem to be characterized by a higher severity
and a faster progression rate (when compared to
the rest of the world). Indeed, in one Moroccan
cohort including 380 patients with MS (372 of
whom were Caucasian), the time to progression
to an Expanded Disability Status Score (EDSS) of
6 was only 10 years. Importantly, this higher
severity seems to be independent of the delay in
diagnosis (which was 2.5 years in the Moroccan
series). Other studies have reported similar
trends in severity [17, 18], and Sidhom et al.
highlighted that the higher severity in North
Africans is independent of patient location
(within or outside Africa) [19], which suggests a
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genetically driven explanation. Kissani also
shared the results of a questionnaire he sent to
his African colleagues—in an attempt to
understand the true prevalence of MS in African
countries—highlighting not only the low
number of MS cases reported, but also the
comparably high incidence of neuromyelitis
optica (NMO) and the problematic lack of
resources and therapies (in most cases, the only
treatments available were corticosteroids). Kis-
sani finished his presentation by underpinning
the necessity of more studies (supported by
robust collaborations) to understand—and
tackle—the MS low prevalence/high severity
dichotomy in Africa.
Fu-Dong Shi (Tianjin Medical University
General Hospital, China) discussed the MS
landscape in China, focussing on the latest
advances in the diagnosis and treatment of both
MS and NMO Spectrum Disorder (NMOSD). The
prevalence of MS in China is unknown; how-
ever, when data from Hong Kong and the
neighbouring countries of Japan and Korea are
taken into consideration, MS prevalence in
China is estimated to be between 5 and 10 cases
per 100,000 inhabitants, while the ratio of
MS:NMOSD seems to be 2:1. Regarding treat-
ments, while not all currently used drugs are
available in China, the scenario is quickly
changing, and drugs such as fingolimod, dime-
thyl fumarate and dalfampridine are in the
pipeline for a quick approval. According to Shi,
one of the greatest diagnostic dilemmas con-
cerning MS in China is the prediction of con-
version after a clinical isolated syndrome (CIS)
in the presence of changes in white matter. In
this respect, Shi presented BioMind, a diagnos-
tic support system that uses deep learning
technology to analyse MRI and computed
tomography images, increasing the accuracy of
diagnosis by 20% (when compared to the
human eye). Other ongoing projects mentioned
by Shi included the utilization of OCT to dis-
cern between MS and NMOSD [20]; the identi-
fication of immune markers able to predict CIS
conversion; the responsiveness to a reduced
dose of rituximab in NMO patients [21]; the
utilization of bortezomib in NMOSD patients
[22]; and the efficacy and safety of tocilizumab
in NMOSD patients.
Regina Papais-Alvarenga (Federal University
of the State of Rio de Janeiro, Brazil) discussed
the prevalence and risk factors for MS in Latin
America (LA), a region characterized by an
heterogeneous and genetically complex popu-
lation. Although LA comprises 20 countries,
most MS studies published to date have been
conducted in only six of these—Brazil, Argen-
tina, Mexico, Colombia, Chile and Cuba.
Overall, LA seems to be an area of low to med-
ium MS prevalence, with rates varying from
0.83 to 21.5 cases per 100,000 inhabitants [23].
More specifically, in Brazil, a systematic review
by Pereira et al. reported MS prevalence rates
varying between 1.36 (in the northeastern
region) and 27.2 (in the southern region) per
100,000 inhabitants [24]. This distribution is
likely driven by genetic factors, although envi-
ronmental risk factors may also play a role in
the dynamics of MS prevalence [25, 26]. Famil-
ial MS cases seem to be rare in the countries of
LA, with values ranging from 3.3% (in Mexico)
to 10.5% (in Buenos Aires). However, the rela-
tive frequency of NMO in NMO ? RRMS cases
in LA is higher than that reported for Europe
and Australia: in fact, a multicentre study
involving 1917 patients revealed NMO relative
frequencies ranging from 2.1% (in Argentina) to
43.3% (Venezuela) [27]. This variation was
related to ethnicity, with higher frequencies
found among non-white populations, a finding
which confirms results from previous studies.
Jan Hillert (Karolinska Institutet, Sweden)
presented the Swedish MS Registry and dis-
cussed the implications of registry data for
research. The Swedish MS Registry was started
on 2000 and became web-based in 2004: it
currently includes data pertaining to 17,000
patients (of the 20,500 MS patients in Sweden)
from all 64 neurology units that exist across the
country [28]. At the start of a consultation, by
opening a patient’s registry, the physician has
immediate access to a set of data providing
valuable information, including a temporal line
representing patient progression [according to
the EDSS and MS Severity Score (MSSS)], current
and past DMDs and other treatments, MRI
results, MS attacks and functional tests, among
other information [28]. Importantly, the long-
term clinical data in the Swedish MS Registry
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can be used to improve our understanding of
MS. In this context, Hillert provided several
examples in which the Swedish MS Registry was
used as the basis of pertinent investigations in
the field. Among these was the identification of
MS progression trends in Sweden (namely, a
tendency towards a slower progression and a
decreased risk of reaching EDSS 3, 4 and 6 [29]; a
decrease in MS costs [30]; and a lower incidence
in primary progressive MS [31]). Moreover, reg-
istry data have also been used to identify risk
factors and predict secondary progressive MS
[32] and to identify socioeconomic conse-
quences of disease progression [33]. Finally, the
Swedish MS Registry was useful to show that the
risk of MS progression can be ameliorated by the
utilization of DMDs [34], as well as by an early
introduction of these therapies [35, 36], and
that smoking cessation can slow down disease
progression [37]. Hillert also mentioned that an
unification of several national Swedish MS reg-
istries has recently taken place, allowing the
integration of data and making available larger
cohorts for investigational studies (three of
which are currently ongoing) and for post-ap-
proval safety studies (also being launched).
MS-RELATED DISEASES
AND DIFFERENTIAL DIAGNOSIS
Despite the remarkable advances achieved in
the fields of imaging, pathology and immunol-
ogy in recent years, MS diagnosis remains
challenging [38]. One important—and many
times puzzling—step is to differentiate MS from
other neuroinflammatory disorders, namely
those of a demyelinating nature. Two renowned
neurologists—Francesc Graus and Jacqueline
Palace—were invited to the 5th International
Porto Congress of Multiple Sclerosis to discuss
the diagnosis, outcomes and therapeutic
options of two neuroinflammatory disorders
other than MS.
Francesc Graus (University of Barcelona,
Barcelona) discussed the physiopathology of
autoimmune encephalitis, highlighting the
need to loosen the boundaries between the
fields of autoimmunity and neurodegeneration.
Starting with a retrospective overview of the
topic, Graus mentioned that the relationship
between limbic encephalitis and cancer has
been known for over 50 years, with Corsellis
et al. first describing patients (n = 3) with this
form of encephalitis and small-cell lung cancer
in 1968 [39]. The subsequent identification of
antibodies reacting with both intracellular brain
and tumour antigens suggested that limbic
encephalitis was actually immune mediated,
although by then this immune attack was con-
sidered to be mainly driven by T-cell infiltrates
[40]. Finally, the identification of different
antibodies reacting against intracellular and
neuronal surface antigens led to the current
belief that these antibodies are, indeed, the
main pathogenic agents, a finding which sup-
ports the development of different forms of
encephalitis. Importantly, serological tests
should not be mandatory when considering the
diagnosis of autoimmune encephalitis and
starting the treatment. An initial diagnosis of
autoimmune encephalitis can be made on the
basis of the patient’s clinical symptoms and
using conventional tests, as described in Graus
et al. [41]. Still, the identification of which
antibodies are present is important to confirm
the diagnosis and determine patient prognosis
and the likelihood of cancer development. Anti-
LGI1 is one of the most common antibodies
related to encephalitis: patients with this form
of the disease are mostly men (60–70%) and
between 50 and 70 years of age and, in most
cases (87%), have the limbic phenotype.
Importantly, patients with anti-LGI1
encephalitis develop faciobrachial dystonic sei-
zures before encephalitis itself and can therefore
be misdiagnosed. Anti-NMDA receptor
(NMDAR)-associated encephalitis, which
mainly affects young women and children, is
another important form of the disease. Inter-
estingly, patients with this form of encephalitis
typically present with psychiatric symptoms,
with the neurological signs following shortly
thereafter. It should also be taken into consid-
eration that autoimmune encephalitis, and
namely anti-NMDAR encephalitis, can be trig-
gered by herpes simplex encephalitis [42]. The
best therapy for these diseases is still under
discussion: the development of clinical trials is
hindered by the low number of cases and,
Neurol Ther
therefore, all knowledge gathered to date is of a
retrospective nature. Steroids are the most
common first-line therapy for anti-LGI1
encephalitis (with rituximab as the most com-
mon second-line therapy), and most patients
have positive outcomes. Still, around 25% of
patients become fully dependent or acquire
severe cognitive deficits [43]. The scenario is
similar with the anti-NMDAR forms of
encephalitis, with approximately 80% of
patients showing a good outcome after
immunotherapy or tumour removal [44].
Importantly, patients who switched therapy
after an unsuccessful first-line treatment had
better outcomes that those who did not switch,
suggesting the importance of considering alter-
native treatments in difficult cases [44].
Jacqueline Palace (University of Oxford, UK)
gave an overview of myelin oligodendrocyte
glycoprotein (MOG) antibody disease, focussing
on its distinctive features and diagnosis criteria.
MOG is a structural glycoprotein found at the
surface of myelin in the central nervous system
(CNS). Anti-MOG disease, which is distinct
from MS and mutually exclusive from anti-
aquaporin 4 (AQP4) disease, can be classified
into multiple clinical phenotypes, including
acute disseminated encephalomyelitis, trans-
verse myelitis, optical neuritis (ON) and cortical
disease. Two large cohorts of anti-MOG patients
have been recently characterized and shown to
have a remarkably similar distribution of fea-
tures, namely the female:male ratio (57 and
49% females), the incidence of relapsing disease
(46 and 42%), the percentage of Caucasian
patients (85.8 and 92.9%) and the predomi-
nance of ON (unilateral or bilateral) as the main
disease manifestation [45, 46]. The results of
these studies are utterly important to our
understanding of the epidemiology of anti-
MOG disease, and are referred to several times
by Palace, as seen below; however, it should be
kept in mind that both studies were carried out
in ‘‘Caucasian’’ countries and, therefore, the
possibility of having different trends in coun-
tries where the percentage of Caucasian people
is different from those noted above cannot be
excluded. Regarding diagnosis, Palace high-
lighted the Matthews criteria of ‘‘at least one
lesion adjacent to the body of the lateral
ventricle and in the inferior temporal lobe; or
the presence of a subcortical U-fiber lesion; or a
Dawson’s finger-type lesion’’ for distinguishing
patients with MS from those with NMOSD with
a sensitivity of 92%, specificity of 96%, 98%
positive predictive value and 86% negative
predictive value [47]. These imaging findings
may, however, be similar in anti-MOG disease.
With respect to the course of disease, both
cohorts mentioned above were again very sim-
ilar, with 41 and 43% of patients relapsing
within 24 months [45, 46]. Interestingly, most
of these patients relapsed in a rather early phase
of the disease. Additionally, no relapses were
reported for those patients who became anti-
MOG negative (28% of the initial patients, 88%
of whom stayed negative until the end of the
follow-up), and therapy for periods longer than
3 months seemed to reduce the risk of relapse
[45]. Disability seemed to affect patients with
anti-AQP4 disease more severely than those
with anti-MOG disease, irrespective of the
severity of the relapses [45, 46]. Still, a consid-
erable number of anti-MOG patients developed
sphincter-related disability, namely permanent
bladder dysfunction (28%), bowel dysfunction
(20%) and erectile dysfunction (21% of male
patients) [45]. The best treatment for patients
with anti-MOG disease is still under discussion:
a possible algorithm, recently published,
includes testing for anti-MOG antibodies after
an initial 6-month course of corticosteroids and
considers extra courses for patients who test
positive; patients with late relapses are candi-
dates for long-term immunosuppression [48].
The best immunosuppressive drug for these
patients, however, is yet to be identified: in fact,
two recent studies that examined the relapse
rate of patients with anti-MOG disease on dif-
ferent treatments yielded distinct values for
similar therapies [49, 50].
MEDICAL MANAGEMENT
AND PATIENTS’ DAILY LIFE
ACTIVITIES
The impact of MS and other demyelinating
diseases, such as NMOSD, on patients’ QOL is
both devastating and complex. The importance
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of setting thresholds to define an early and
effective medical intervention was the theme of
one of the talks discussing this topic; others
were focused on the cognitive impairment
associated to MS, and on family planning and
pregnancy in patients with MS and NMOSD.
Jeremy Hobart (University of Plymouth, UK)
presented the MS Brain Health Initiative
(https://www.msbrainhealth.org/), which is
based on the importance of a time-efficient
approach to the different stages of the disease,
with the ultimate aim to improve MS care at an
international level. Importantly, whereas the
dysfunction generated by other diseases can be
ameliorated or cured with organ transplanta-
tion, MS patients have no such option: the
accumulated damage to the CNS is mostly irre-
versible. As such, a time-wise care strategy able
to prevent the accumulation of such damage
would represent an immense benefit to MS
patients. In this context, the ‘‘Brain Health—
Time Matters in Multiple Sclerosis’’ report
details a series of explicit recommendations
pertaining to the urgency of care at every stage
of MS [51]. Following the publication of this
report, and in an attempt to turn these recom-
mendations into tools that can be used in daily
clinical practice, a group of neurologists carried
out a Delphi methodology-based study to define
the optimal time frames that should be met in
different stages of the disease [52]. These time
frames were divided into ‘core’, ‘achievable’ and
‘aspirational’, reflecting minimum, good and
high standards of MS care, respectively. For
example, the time frame within which a diag-
nostic workup should be completed after refer-
ral to a neurologist is 2 months (core), 4 weeks
(achievable) or 7 days (aspirational) [52]. Clini-
cal teams are thus provided with international
standards against which they can compare their
own performance, thereby enabling them to
identify their own strengths and weaknesses,
and to focus on areas that need improvement.
To further facilitate this, quality improvement
tools—based both on physicians’ and patients’
reports—are being developed and tested (pilot
phase).
Dawn Langdon (Royal Holloway, University
of London, UK) discussed the importance of
cognitive impairment in MS and its impact on
patients’ QOL. Cognitive deficits are common
among MS patients and are known to interfere
in different life domains [53, 54], with perhaps
one of the most important being employment
status [55, 56]. Moreover, cognitive impairment
also affects the patient–doctor relationship and
the shared process of therapeutic decision-
making, as recent therapies and DMDs often
carry with them an intricate network of risks
and benefits that is notoriously hard to per-
ceive. Interestingly, cognition is an important
predictor of neurological outcomes and mor-
bidity/psychosocial risks among MS patients. In
terms of neurological outcomes, cognitive
impairment is known to be related with the risk
of conversion to MS after CIS [57], while cog-
nitive deficits assessed immediately after diag-
nosis can predict the degree of disability and
disease progression several years later [58, 59].
Regarding morbidity risks, cognition is known
to be related with medication adherence [60],
decision-making ability and speed [61, 62],
symptom management [63], fear of falling and
actual falls [64–71] and driving safety [72–75].
Finally, with respect to psychosocial risks, cog-
nition has been reported as being linked to
employment and working status [76], psychi-
atric disturbances and associated co-morbidities
[77, 78], financial abilities [79, 80], participation
in domestic, leisure and outdoor activities
[81–85], social cognition and emotional aware-
ness [86, 87] and caregivers’ QOL [88, 89]. Given
all of the above, the importance of neuropsy-
chological assessment in MS patients is indis-
putable. However, Langdon highlighted that
cognition self-report is often unreliable, being
confounded by a number of different factors
(such as depression, anxiety, fatigue, conscien-
tiousness, perceived stress and self-efficacy)
[90–93]. In this context, a committee of experts
has analysed and recommended a set of tools—
named the Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS)—
that aims to allow a fast cognitive assessment of
MS patients in small centres (which may lack
neuropsychological experts) at an international
level [94].
Maria Isabel Leite (University of Oxford, UK)
discussed the implications of pregnancy in
patients with NMOSD, focussing particularly on
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those with anti-AQP4 antibody disease. Preg-
nancy is a matter that should be taken into
account because most NMOSD patients are
female and of child-bearing age: in fact,
according to Kim et al., 84–90% of NMOSD
patients are female, and the average age at onset
varies from 33 to 43 (being slightly lower for
Asian and African-American/African-European
patients) [95]. Leite divided her presentation
into two main topics, with the first focussing on
the effects of pregnancy on NMOSD disease
activity, and the second focussing on the
influence of NMOSD on pregnancy outcomes
and foetal development. With respect to the
former, several retrospective studies have
shown that the relapse rate may increase
slightly during the third trimester of pregnancy
(although in a non-significant manner) and is
generally higher in the 3- to 6-month post-
partum period [96–98]. Moreover, Simizu et al.
reported that suboptimal immunosuppression
seems to increase the risk of pregnancy-related
relapses [99]. Regarding the impact of NMOSD
on pregnancy outcomes, the studies available to
date suggest an increased risk of miscarriage
that seems to be independent of maternal age
and miscarriage history (at least for pregnancies
initiated after or up to 3 years before NMOSD
onset) [100]. Additionally, patients with
NMOSD have also an increased risk of
preeclampsia, which is apparently independent
of NMOSD onset but instead related with the
presence of other autoimmune disorders [100].
On the other hand, and with the exception of a
few reports on pre-term births without major
complications, there are very few reports of
complications in children born from NMOSD-
afflicted mothers. Leite also highlighted that,
although there are no studies on the safety of
drugs used during pregnancy in NMOSD
patients, one can extrapolate from what is
known in other diseases that azathioprine,
cyclosporine, tacrolimus, prednisolone, intra-
venous immunoglobulin and plasma exchange
are safe therapeutic options. Conversely,
methotrexate, mycophenolate and rituximab
should be used with extreme caution. Overall,
in Leite’s opinion, NMOSD should not be con-
sidered to be a contraindication for pregnancy,
but rather patients should be thoroughly
informed and closely monitored. Moreover, the
choice of an adequate and effective treatment is
a crucial step towards a positive outcome.
Elisabeth G. Celius (Oslo University Hospital,
Norway) also discussed pregnancy and family
planning, but with a focus on MS patients
instead of patients with NMOSD, highlighting
the increasing rate of pregnancy among MS
patients in recent years [101]. Interestingly, MS
does not seem to impact fertility, although it
might be associated with sexual dysfunction.
However, pregnancy itself causes a number of
major immune changes, one of which is an
increased immune tolerance. The clinical
implications of this increased immune toler-
ance on the disease course were described in
1998 by Confavreux et al. [102] and confirmed
20 years later by Bsteh et al. [103]. As in
NMOSD, it would appear that the rate of MS
relapses decreases during pregnancy and
increases in the post-partum period [102, 103].
That the same pattern was observed in cohorts
separated by 20 years shows that the availability
of modern treatments has had little impact on
these pregnancy-related variation in relapse
rate. As shown in the MSBase registry, the
number of pregnancies initiated while on
DMDs has increased over the last 12 years. The
median time of DMD exposure is 30 days, sug-
gesting that most women interrupt treatment
when pregnancy is confirmed [104]. Interrupt-
ing treatment because of a planned or con-
firmed pregnancy carries an increased risk of
rebound of disease activity, which is particularly
relevant when therapy with fingolimod and
natalizumab is interupted. In addition, some of
the more commonly prescribed hormonal
treatments meant to increase fertility in women
who are trying to conceive might trigger disease
activity. In contrast, glatiramer acetate may
now be continued until pregnancy is estab-
lished, and interferons also seem to be safe.
Interferons and glatiramer acetate may be
appropriate choices for women with mild to
moderately active disease, whereas immune
reconstitution therapy, using alemtuzumab or
cladribine, should be considered for women
with high disease activity before conception.
Regarding alemtuzumab, a preliminary study
reported by Celius et al. at the 34th Congress of
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the European Committee for Treatment and
Research in Multiple Sclerosis (ECTRIMS 2018)
has shown some promising results, particularly
in terms of the absence of disease activity dur-
ing pregnancy and post-partum in women with
pre-treatment high disease activity [105].
Exclusive breastfeeding might offer some pro-
tection against MS relapses, although the
reports published to date on this subject are
conflicting [106, 107]. While none of the drugs
are approved for use during breastfeeding,
interferons, glatiramer acetate and alem-
tuzumab seem to be safe. Overall, future preg-
nancies should be taken into consideration
when initiating therapy in women of child-
bearing age, and women should be informed of
the possible risks related to a pregnancy that are
associated with each of the different therapies
available and the need for contraception. After
giving birth, breastfeeding should be encour-
aged, and an MRI should be performed 4–6
weeks post-partum to assess disease activity. In
the absence of disease activity, patients may
consider continuing breastfeeding, but this
decision should be re-evaluated after 3–4
months. Conversely, the detection of disease
activity requires treatment re-initiation and
usually the interruption of breastfeeding.
BASIC AND APPLIED MOLECULAR
RESEARCH
Molecular research is a key field of MS investi-
gation. As it would be impossible to discuss the
multitude of interesting projects currently
exploring MS-related molecular issues, two
aspects were chosen to be presented at the 5th
International Congress: the role of Epstein–Barr
virus (EBV) infection in MS development, and
the importance of identifying biomarkers and
their potential in MS diagnosis and monitoring.
Gulfaraz Khan (United Arab Emirates
University, UAE) dedicated his talk to the dis-
cussion of the role of EBV infection in MS
immunopathology. EBV is an ubiquitous dou-
ble-stranded DNA virus known to have
tumourigenic properties. Its detection has been
improved by a very specific and sensitive in situ
hybridization technique developed by Khan
and colleagues, which is based on the recogni-
tion of two small RNAs—EBER1 and EBER2
(EBV-encoded RNA 1 and 2)—that are expressed
in all forms of infection known to date
[108–110]. The association between EBV infec-
tion and MS has been studied for a long time,
and numerous studies, such as those of Cepok
et al. [111], Haahr et al. [112] and Ponsonby
et al. [113], have provided indirect evidence
suggesting the existence of a relationship. In
fact, individuals with EBV immunoglobulins are
at an increased risk of developing MS, and vir-
tually all (99.5%) patients with MS are EBV
seropositive. Moreover, the levels of anti-EBV
antibodies and specific T cells are higher in MS
patients when compared to controls both before
and after disease onset. The first direct evidence
of the EBV–MS link came from the study of
Serafini et al., who detected EBV infection in
brain-infiltrating B cells and plasma cells in 21
of 22 patients with MS [114]. Interestingly, at
least three studies published afterwards found
no evidence of such a link [115–117], which has
been suggested to be a consequence of technical
issues and different sampling procedures [118].
Khan’s group has recently examined 1055
samples extracted from MS and non-MS
patients and shown that EBV is present in 91 of
101 (90%) MS patients, but in only five of 21
(24%) patients with other neurological condi-
tions [119]. Moreover, none of the samples were
positive for other common herpesviruses [HSV-
1 (Herpes simplex virus 1), CMV [Cy-
tomegalovirus], HHV-6 [Human Herpesvirus 6])
[119]. Interestingly, the virus was transcrip-
tionally active in only a few of the cells, being
latent in the majority of them, which may be a
mechanism by which it escapes immune
surveillance [119, 120]. Another interesting
finding made by this group was that the virus
was not only present in B cells, as expected, but
also in astrocytes and microglia [119]. Khan and
collaborators are currently working with an
animal model of EBV infection [121], and the
promising results from this study will certainly
contribute to a better understanding of the
impact of EBV in MS immunopathology.
Ineˆs Mendes Pinto (International Iberian
Nanotechnology Laboratory, Portugal) dis-
cussed the pertinence of using biosensors in
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neuroimmunological diseases and presented a
device, designed and fabricated in her labora-
tory, that is able to detect different MS
biomarkers. A biosensor is a device conceptually
composed of a sensing module that is able to
selectively recognize a given biomarker (i.e.
anything from nucleic acids to entire cells) and
a transducing module that translates the
recognition reaction into a measurable signal.
Ideally, a biosensor should be highly specific
and sensitive, have minimal requirements in
terms of sample volume and technical expertise
and be efficient in terms of detection limits and
time [122]. In the context of neuroimmunol-
ogy, and particularly in the case of MS, there is a
high demand for new diagnostic methods: the
conventional platforms are usually ELISA (en-
zyme-linked immunosorbent assay)-based,
restricted to central laboratories (as they require
technical expertise), time-consuming (around
24 h from sampling to output reading) and
costly. Other limitations include the require-
ment of large samples (50 lL) and the impossi-
bility to detect and monitor different
biomarkers simultaneously (i.e., multiplex). In
this context, Mendes Pinto’s team has devel-
oped a portable biosensor that overcomes most
of these limitations. This device is an electro-
chemical-based system able to detect different
MS biomarkers using 1 lL of body fluid (either
cerebrospinal fluid, blood serum, tears or oth-
ers) in less than 10 min and without requiring
technical expertise. Specificity of the biomark-
ers is ensured by the chemical irreversible
immobilization system used to cross-link the
antibodies to the chip. Sensitivity depends on
the biomarker(s) being detected, but is generally
higher than that obtained with conventional
tests (e.g. those for the detection of tumour
necrosis factor a is around 40-fold more sensi-
tive than the ELISA-based assays) [123]. More-
over, this biosensor can be integrated into a
reader and connected to a computer or to a
smartphone, from which the results can be
directly read. All of the above characteristics
make this chip a convenient and user-friendly
bedside diagnosis and monitoring tool. In terms
of cost-efficiency, this device can be produced
in batches, which lowers its production cost.
Overall, this biosensor—which is currently in its
clinical validation stage—is a promising tool to
diagnose and monitor MS patients in a rapid,
cheap, time-efficient and minimally invasive
fashion.
ADVANCES IN MRI AND OTHER
IMAGING TECHNIQUES
Magnetic resonance imaging remains a pivotal
tool in MS diagnosis and monitoring. Impor-
tantly, advances in this and other imaging
techniques are improving the diagnostic ability
and monitoring capacity in MS medical care.
Issues discussed in this section included MRI
itself, other complementary approaches and the
value of applying artificial intelligence to three-
dimensional (3D) image analysis and auto-
mated segmentation.
Claudia Chien, who represented the Dr
Friedemann Paul laboratory (Charite´-Univer-
sita¨tsmedizin, Germany), presented the latest
advances in imaging tools for application in
neuroimmunological disorders, namely those
related to MRI and OCT. Regarding MRI tech-
niques, analysis of the central vein sign repre-
sents an important development: the presence
of more than 50% perivenular lesions in the
brain enables MS to be distinguished from other
inflammatory vasculopathies with 100% diag-
nostic accuracy [124]. Another major improve-
ment to the field may be the utilization of
cortical thickness atlases coupled with the
mapping of myelin content [125, 126], as this
approach may facilitate the analysis of the typ-
ical cortical and juxtacortical lesions in MS,
which are often difficult to visualize using
standard MRI. The analysis of functional visual
networks by resting-state functional MRI has
also brought some interesting results: the pres-
ence of ON was associated with a stronger
connectivity in the visual network of patients
with NMOSD or those who had suffered a CIS
[127, 128]. Finally, the improvement of auto-
mated techniques for the assessment of spinal
cord atrophy, as well as the inclusion of this
assessment into the routine monitoring of
patients with MS and NMOSD, has now been
pinpointed as an important research area for the
future [129]. In this context, Gros et al. have
Neurol Ther
recently published a method to segment spinal
cord (and intramedullary) MS lesions on a
variety of MRI sequences [130]. There have also
been some advances in OCT recently: this high-
resolution imaging technique enables thickness
analysis of individual retinal layers, two of
which have proven to be particularly important
in the context of MS—the retinal nerve fibre
layer (RNFL) and the ganglion cell/inner plexi-
form layer (GCIPL). In fact, in one study, the
most conspicuous differences between the eyes
of MS and control patients were the peripapil-
lary RNFL and the macular GCIPL [131]. Zim-
mermann et al. have also demonstrated that the
thickness of the GCIPL may inform on future
disease activity and risk assessment of conver-
sion to MS in CIS patients [132]. As for NMOSD
research, OCT-based studies have shown that
GCIPL loss occurs independently of ON attacks
in AQP4-positive patients [133] and that the
presence of prior ON can be assessed with a
relatively high sensitivity using thresholds of 6
and 3 lm differences in RNFL and GCIPL
thickness, respectively [134]. Overall, Chien
considered that multi-modal imaging is the
future, with the integration of different tech-
niques allowing for a more accurate diagnosis
and monitoring of neuroinflammatory diseases.
Darin Okuda (UT Southwestern Medical
Center, USA) argued on the possibilities offered
by artificial intelligence in the field of medical
imaging, focusing on the potential of auto-
mated 3D analysis of white matter lesions in
MS. MRI, by itself, has revolutionized the diag-
nosis and understanding of MS pathology.
Moreover, it can inform on disease progression
risks: the number of lesions after an isolated
attack is known to be related with the risk of
conversion to MS, whereas the temporal profile
by which lesions accumulate over the initial
years of the disease is helpful in predicting the
risk of secondary progression later on. However,
neurologists are often confronted with clinico-
radiological paradoxes, i.e. patients whose MRI
examination reveals devastating lesions but
who are neurologically well, and patients who
are in a poor neurological state but whose
examination reveals nothing but small radio-
logical changes. Indeed, it is now accepted that
CNS lesions do not necessarily inform on the
patients’ clinical condition at the moment:
these lesions are very dynamic and may not
have clinical manifestations until several years
later. Accordingly, Kantarci et al. have followed
453 subjects who suffered radiologically isolated
syndromes; of these, 128 progressed to symp-
tomatic MS, 15 of which evolved to PPMS [135].
According to Okuda, the value of 3D analysis of
white matter lesions may reside in an improved
ability to diagnose, distinguishing different
types of lesions and providing patients with
fine-tuned and personalized medical care. The
automatic segmentation of the lesions, as
opposed to the manual procedures, is often
criticized; however, as these processes rely on
the distinction of subtle shades, machine
learning systems tend to perform better than
the human eye. Whereas previous attempts at
automatic segmentation focussed on lesion
volume, the newest techniques can accurately
determine shape and surface structure. These
characteristics may inform on the origin of
disease, provide insights into the extent of
injury and even deliver some information on
the capacity for self-remyelination. Addition-
ally, 3D data may allow the identification of
different pathologies within the brain of a sin-
gle patient, resulting in more accurate and
effective medical care.
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